We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
XBiotech has agreed to offload its human antibody bermekimab to Janssen Biotech, a subsidiary of Janssen Pharmaceutical Company of Johnson & Johnson, in a deal worth up to $1.35bn.